Tokyo, Apr 21, 2006 (JCN) - Novartis Pharma announced on April 20 that it had obtained additional approval for Zometa Injection 4mg, its proprietary osteoclastic inhibitor, from the Ministry of Health, Labor and Welfare. The agent is currently available for the treatment of bone metastasis in multiple myeloma (MM) and solid tumor. Zometa, a bisphosphonate agent, is currently available in over 90 countries worldwide.
